Alnylam Pharmace. buy William Blair
Start price
08.01.24
/
50%
€168.80
Target price
08.01.25
-
Performance (%)
37.26%
End price
09.01.25
€231.70
Summary
This prediction ended on 09.01.25 with a price of €231.70. The BUY prediction by William_Blair for Alnylam Pharmace. saw massive gains of 37.26%. William_Blair has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. William_Blair has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | -0.651% | -0.651% | 23.205% |
| iShares Core DAX® | -1.104% | -6.084% | 3.201% |
| iShares Nasdaq 100 | 0.328% | 2.327% | 20.240% |
| iShares Nikkei 225® | -1.082% | -7.987% | 27.550% |
| iShares S&P 500 | -0.055% | 0.880% | 14.887% |
Comments by William_Blair for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for ALNY provided by MarketBeat
In the thread Trading Alnylam Pharmace.
Die von William_Blair gewählte maximale Laufzeit wurde überschritten